Skip to Content

TorreyPines Therapeutics to Present Tezampanel Phase IIb ClinicalData for Acute Migraine at 50th Annual Scientific Meeting of theAmerican Headache Society

LA JOLLA, Calif., June 23, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists.

Posted: June 2008

View comments

(web2)